Komori

Supplementary Explanatory Materials for the Second Quarter Financial Results for the Fiscal Year Ending March 2027

Supplementary dataFirst half, FY ending Mar 2027Published 2026-11-13 15:30

In the first half of the fiscal year ending March 2027, net sales and profit exceeded the year-earlier period, driven by the start of operations at the new building and strengthened sales efforts. The full-year forecast was left unchanged, but the outlook for the second half is conservative and incorporates cost and raw-material procurement risks.

Contents of this document

Supplementary materials to the earnings summaryFY2027/3 Q214 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥4,466 million+32.4%
Operating profit¥311 million
Ordinary income¥304 million
Net income¥197 million
Results for the three months of the current quarter
Net Sales
¥2,348 million+39.8%
Operating profit
¥260 million
Ordinary income
¥256 million
Net income
¥156 million
Ordinary income margin
10.9 %
yoy_change_pp9.5
Adjusted EBITDA
¥569 million
Adjusted EBITDA margin
24.3 %
yoy_change_pp12.5
Full-year earnings forecast
Net Sales
¥10,000 million
Functional Materials
¥3,300 million
Pharmaceuticals
¥4,100 million
Bio
¥2,600 million
Operating profit
¥910 million
Ordinary income
¥890 million
Net income
¥640 million
Adjusted EBITDA
¥2,210 million
Ordinary income margin
8.9 %
Adjusted EBITDA margin
22.1 %
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales44.7 %
Functional Materials53.6 %
Pharmaceuticals32.7 %
Bio52.2 %
Operating profit34.2 %
Ordinary income34.2 %
Net income30.9 %
Adjusted EBITDA41.7 %
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Sales are progressing at a steady pace. However, the full-year outlook is considered conservative.
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Revenue growth effect¥5.2 100 million
  • Improved product mix¥2.1 100 million
  • Loss from special factors¥-0.9 100 million
  • Depreciation and amortization¥-2.5 100 million
  • Personnel expenses¥-0.9 100 million
  • Other fixed costs¥-0.1 100 million
  • Research and Development Expenses¥-0.2 100 million
  • Non-Operating Income¥0.2 100 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
  • Seasonality of second-half sales
    DetailsThe second half is expected to remain weighted toward the second half. Second-half sales in the pharmaceutical field are forecast at 2.1 times first-half sales.
  • Raw Material Procurement Risk
    DetailsThe outlook incorporates substantial risks from the uncertain cost environment and raw-material procurement conditions.
  • Second-half capital expenditure¥6 100 million
New initiatives
  • Start of operations at the new buildings (Buildings D and FP-4)
  • Increase in sales staff
  • LP investment in the DCIP Fund
  • Joint research with 光オンデマンドケミカル
  • Investment in イムノロック社
  • Consider securing personnel at the Izumo Plant and acquiring additional land
Key KPIsA metric the company considers important as a management benchmark.
  • New orders (first half)¥67.9 100 million
    Year on year against the same period last yearRecord high
  • New orders (standalone second quarter)¥27.3 100 million
  • Order backlog¥87.2 100 million
    Year on year against the same period last yearReached a new record high
  • Remaining order lead time11 Month
  • Development-stage sales mix27 %
  • Productivity per employee4 % vs. FY3/25
  • Equity ratio67.1 %
  • FCF¥933 million
Segment results
  • Functional Materials
    Net Sales1,768
  • Pharmaceuticals
    Net Sales1,341
  • Bio
    Net Sales1,356
Medium-term management plan targets
  • TargetIncrease sales staff to approximately twice the current level
    Actual resultsIncreased to 1.4 times the previous level
  • TargetAnnual orders of ¥12.5 billion
    Actual resultsFirst-half orders in FY3/27 of ¥6.7 billion
  • TargetIncrease production capacity by 150%
    Actual resultsStarted operations at the new building
  • TargetIncrease productivity per employee by 20% (vs. FY3/25)
    Actual resultsIncreased by 4% (vs. FY3/25)
Financial targets
DOE target1.8 %
Actual equity ratio67.1 %
Equity ratio unit%
Risk amount incorporated into the outlookThe amount representing the range of variation the company expects in its forecast.
¥0.1 100 million per quarter
DetailsCosts to address raw-material procurement risks
Orders received and order backlog
New orders received¥67.9 100 million
Order backlog¥87.2 100 million
Number of employees
Changes and hiring plans during the periodIncreased the sales staff to 1.4 times the previous level. Proceeding with efforts to secure personnel at the Izumo Plant
Capital expenditures
¥6 100 million scheduled for the second half of the fiscal year ending March 2027
Annual Dividend
Annual Dividend33 Yen per share
Interim16 Yen per share
End of period17 Yen per share
Acquisition of treasury shares
Number of shares to be acquiredEquivalent to 1.55% of issued shares
Acquisition price¥152 million
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings summary
Fiscal Period CoveredFY2027/3 Q2
Net Sales¥4,466 million (YoY +32.4%)
Operating profit¥311 million
Ordinary income¥304 million
Net income¥197 million
Results for the three months of the current quarterNet Sales ¥2,348 million (YoY +39.8%) / Operating profit ¥260 million / Ordinary income ¥256 million / Net income ¥156 million / Ordinary income margin 10.9 % / Adjusted EBITDA ¥569 million / Adjusted EBITDA margin 24.3 %
Full-year earnings forecastNet Sales ¥10,000 million / Functional Materials ¥3,300 million / Pharmaceuticals ¥4,100 million / Bio ¥2,600 million / Operating profit ¥910 million / Ordinary income ¥890 million / Net income ¥640 million / Adjusted EBITDA ¥2,210 million / Ordinary income margin 8.9 % / Adjusted EBITDA margin 22.1 %
Progress against full-year forecastNet Sales 44.7 % / Functional Materials 53.6 % / Pharmaceuticals 32.7 % / Bio 52.2 % / Operating profit 34.2 % / Ordinary income 34.2 % / Net income 30.9 % / Adjusted EBITDA 41.7 %
Self-assessment against the planSales are progressing at a steady pace. However, the full-year outlook is considered conservative.
Segment resultsSegment Functional Materials / Net Sales ¥1,768 million / yoy_pct ¥25.4 million, Segment Pharmaceuticals / Net Sales ¥1,341 million / yoy_pct ¥-5.3 million, Segment Bio / Net Sales ¥1,356 million / yoy_pct Not disclosed
Breakdown of Factors Affecting the ChangeFactors Revenue growth effect / Amount ¥5.2 100 million, Factors Improved product mix / Amount ¥2.1 100 million, Factors Loss from special factors / Amount ¥-0.9 100 million, Factors Depreciation and amortization / Amount ¥-2.5 100 million, Factors Personnel expenses / Amount ¥-0.9 100 million, Factors Other fixed costs / Amount ¥-0.1 100 million, Factors Research and Development Expenses / Amount ¥-0.2 100 million, Factors Non-Operating Income / Amount ¥0.2 100 million
Key KPIsIndicator name New orders (first half) / Value ¥67.9 100 million / Year on year against the same period last year Record high, Indicator name New orders (standalone second quarter) / Value ¥27.3 100 million / Year on year against the same period last year Not disclosed, Indicator name Order backlog / Value ¥87.2 100 million / Year on year against the same period last year Reached a new record high, Indicator name Remaining order lead time / Value 11 Month / Year on year against the same period last year Not disclosed, Indicator name Development-stage sales mix / Value 27 % / Year on year against the same period last year Not disclosed, Indicator name Productivity per employee / Value 4 % (vs. FY3/25) / Year on year against the same period last year Not disclosed, Indicator name Equity ratio / Value 67.1 % / Year on year against the same period last year Not disclosed, Indicator name FCF / Value ¥933 million / Year on year against the same period last year Not disclosed
Number of employeesNumber of Employees Not disclosed / Changes and hiring plans during the period Increased the sales staff to 1.4 times the previous level. Proceeding with efforts to secure personnel at the Izumo Plant
Assumptions Underlying the Business OutlookItem Seasonality of second-half sales / Details The second half is expected to remain weighted toward the second half. Second-half sales in the pharmaceutical field are forecast at 2.1 times first-half sales., Item Raw Material Procurement Risk / Details The outlook incorporates substantial risks from the uncertain cost environment and raw-material procurement conditions., Item Second-half capital expenditure / Value ¥6 100 million
Risk amount incorporated into the outlookDetails Costs to address raw-material procurement risks / Amount ¥0.1 100 million per quarter
Medium-term management plan targetsTarget Increase sales staff to approximately twice the current level / Actual results Increased to 1.4 times the previous level, Target Annual orders of ¥12.5 billion / Actual results First-half orders in FY3/27 of ¥6.7 billion, Target Increase production capacity by 150% / Actual results Started operations at the new building, Target Increase productivity per employee by 20% (vs. FY3/25) / Actual results Increased by 4% (vs. FY3/25)
Financial targetsDOE target 1.8 % / Actual equity ratio 67.1 % / Equity ratio unit %
Annual DividendAnnual Dividend 33 Yen per share / Interim 16 Yen per share / End of period 17 Yen per share
Acquisition of treasury sharesNumber of shares to be acquired Equivalent to 1.55% of issued shares / Acquisition price ¥152 million / Period Not disclosed
Capital expenditures¥6 100 million (scheduled for the second half of the fiscal year ending March 2027)
Orders received and order backlogNew orders received ¥67.9 100 million / Order backlog ¥87.2 100 million
New initiativesStart of operations at the new buildings (Buildings D and FP-4), Increase in sales staff, LP investment in the DCIP Fund, Joint research with 光オンデマンドケミカル, Investment in イムノロック社, Consider securing personnel at the Izumo Plant and acquiring additional land
Items this document does not state (8)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesUnit price and quantity metricsNumber of stores and locationsPayout ratioMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

Supplementary Explanatory Materials for the Second Quarter Financial Results for the Fiscal Year Ending March 2027 | KNC Laboratories Co.,Ltd. (6568) timely disclosure | Komori